A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Leiden University Medical Center
Fudan University
Takeda
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Tianjin Medical University Cancer Institute and Hospital
Brown University
University of Rochester
Ohio State University Comprehensive Cancer Center
St Vincent's Hospital, Sydney
M.D. Anderson Cancer Center
Tufts Medical Center
Al-Azhar University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Northwestern University
M.D. Anderson Cancer Center
AEterna Zentaris
Emory University
University of Washington
OHSU Knight Cancer Institute
Barbara Ann Karmanos Cancer Institute
University of Rochester
University of Manitoba
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
S. Maria Hospital, Terni
Geriatric Oncology Consortium